Functional genomics for breast cancer drug target discovery.
Functional genomics for breast cancer drug target discovery.
复制标题
乳腺癌药物靶点发现的功能基因组学。
DOI：
10.1038/s10038-021-00962-6
复制
发表时间：
2021-09
影响因子：
3.5
通讯作者：
Katagiri T
中科院分区：
文献类型：
--
作者：
Yoshimaru T;Nakamura Y;Katagiri T
乳腺癌是一种异质性疾病，通过多种癌症相关基因中遗传/表观遗传改变的积累，通过多步骤过程发展。目前乳腺癌患者的治疗选择包括手术、放疗和化疗，包括针对每种内在亚型的常规细胞毒性和分子靶向抗癌药物，例如内分泌治疗和抗人表皮生长因子受体2（HER 2）治疗。然而，这些疗法往往不能防止由于耐药性而导致的复发和转移。总体而言，了解乳腺癌发生和进展的分子机制将有助于建立治疗模式，以改善治疗。近年来，随着组学技术的发展，发现了包括癌基因和抑癌基因在内的驱动基因，为分子靶向抗癌药物的开发做出了贡献。在这里，我们回顾了抗癌药物的发展，靶向癌症特异性功能治疗靶点，即MELK（母胚亮氨酸拉链激酶），TOPK（T淋巴因子激活的杀伤细胞起源的蛋白激酶），和BIG 3（布雷菲德菌素A抑制鸟嘌呤核苷酸交换蛋白3），通过全面的乳腺癌转录组学鉴定。
Breast cancer is a heterogeneous disease that develops through a multistep process via the accumulation of genetic/epigenetic alterations in various cancer-related genes. Current treatment options for breast cancer patients include surgery, radiotherapy, and chemotherapy including conventional cytotoxic and molecular-targeted anticancer drugs for each intrinsic subtype, such as endocrine therapy and antihuman epidermal growth factor receptor 2 (HER2) therapy. However, these therapies often fail to prevent recurrence and metastasis due to resistance. Overall, understanding the molecular mechanisms of breast carcinogenesis and progression will help to establish therapeutic modalities to improve treatment. The recent development of comprehensive omics technologies has led to the discovery of driver genes, including oncogenes and tumor-suppressor genes, contributing to the development of molecular-targeted anticancer drugs. Here, we review the development of anticancer drugs targeting cancer-specific functional therapeutic targets, namely, MELK (maternal embryonic leucine zipper kinase), TOPK (T-lymphokine-activated killer cell-originated protein kinase), and BIG3 (brefeldin A-inhibited guanine nucleotide-exchange protein 3), as identified through comprehensive breast cancer transcriptomics.
登录
查看更多内容
影响因子：
5.7
作者：
Gao G;Zhang T;Wang Q;Reddy K;Chen H;Yao K;Wang K;Roh E;Zykova T;Ma W;Ryu J;Curiel-Lewandrowski C;Alberts D;Dickinson SE;Bode AM;Xing Y;Dong Z
通讯作者：
Dong Z
DOI：
10.1158/1078-0432.ccr-09-1314
发表时间：
2010-03-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Houghton PJ
通讯作者：
Houghton PJ
影响因子：
11.5
作者：
Johnston, Stephen R. D.
通讯作者：
Johnston, Stephen R. D.
影响因子：
2.7
作者：
Blot, J;Chartrain, I;Tassan, JP
通讯作者：
Tassan, JP
影响因子：
--
作者：
Alachkar H;Mutonga M;Malnassy G;Park JH;Fulton N;Woods A;Meng L;Kline J;Raca G;Odenike O;Takamatsu N;Miyamoto T;Matsuo Y;Stock W;Nakamura Y
通讯作者：
Nakamura Y